Coherus BioSciences Inc reports results for the quarter ended March 31 - Earnings Summary

Coherus Oncology

12/05/2025 22:56

Coherus BioSciences Inc CHRS.OQ reported a quarterly adjusted loss of 35 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -32 cents.  The mean expectation of six analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -44 cents to -10 cents per share.

Revenue fell 90.1% to $7.60 million from a year ago; analysts expected $54.66 million.

Coherus BioSciences Inc's reported EPS for the quarter was a loss of 49 cents​.

The company reported a quarterly loss of $56.57 million.

Coherus BioSciences Inc shares had risen by 20.0% this quarter and lost 29.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 20.3% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Coherus BioSciences Inc is $6.50

This summary was machine generated from LSEG data May 12 at 09:56 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.21
-0.35
Missed
Dec. 31 2024
-0.13
-0.28
Missed
Sep. 30 2024
-0.13
-0.01
Beat
Jun. 30 2024
-0.29
-0.14
Beat